Belgium· BE-AMP-SAM562897-00

Remsima 120 mg

A infliximab product containing infliximab, registered in Belgium by Celltrion Healthcare Hungary. The same ATC class is registered in 14 of our 19 countries.

ATC L04AB02

Checked against FAMHP / AFMPS (Belgium) on September 26, 2026

Informational only — not a medical device.

Compare price across countriesPer daily dose · free account Ask the assistant about infliximabAnswers with sources · free account Check interactionsSeverity free · mechanism on Growth

Where it is registered

Infliximab is registered in 14 of 19 countries.

Countries holding a registration under ATC L04AB02 (infliximab), each read from that country’s own register.

This record: Belgium, from FAMHP / AFMPS (Belgium)
9 of them publish a price we can compare per daily dose

Search infliximab products by name

Infliximab · ATC L04AB02

14 / 19 countries

Belgiumprice
Canada
Czechiaprice
Denmark
Finlandprice
Franceprice
Icelandprice
Ireland
Netherlands
Norwayprice
Polandprice
Switzerlandprice
United Kingdom
United Statesprice

Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of infliximab costs, country by country.

Normalised to the WHO defined daily dose (3.75 mg), the median price runs from $0.31 in Finland to $24.45 in Switzerland — a ×79 gap.

2 markets with a comparable price for this class
Public list prices, converted to USD at the rate date shown

Open the full comparison — free account Drug prices for market access

Infliximab · price per daily dose (3.75 mg)

USD · FX 28 Sept 2026

CH Switzerland$24.45
FI Finland$0.31

Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

FAMHP / AFMPS (Belgium)

Active substance: Infliximab
Manufacturer: Celltrion Healthcare Hungary
Country: Belgium (BE)
ATC code: L04AB02
ATC class: Infliximab
Defined daily dose: 3.75 mg, P
Reimbursed: Not published by this register
Source register: FAMHP / AFMPS (Belgium)
Last checked: September 26, 2026

Packs & prices · 11

7 priced

be_apb
4984613
EUR 666.21
be_apb
4984621
EUR 1976.68
be_apb
4271052
EUR 1976.68
be_apb
4271045
EUR 666.21
be_apb
4799714
EUR 1890.02
be_apb
4987053
EUR 666.21
be_apb
7746993
be_apb
7748650
be_apb
4932364
EUR 1976.68
be_apb
7729411
be_apb
7740095

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

443 interactions on record for infliximab.

Graded by severity as the source publishes them — 290 severe. Severity grades are free for everyone; mechanism and management come with Growth.

Severity for every pair — free, no plan needed
The source, licence and sync date on every record
Mechanism and what to do for each pair — Growth plan

Check infliximab against other medicines How interaction checks work

Infliximab · interactions on record

443 records

290 severe
146 moderate
7 minor

Most severe, free to view

PrednisoloneA07EA01severe
HydrocortisoneA07EA02severe
PrednisoneA07EA03severe
BetamethasoneA07EA04severe

Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.

Mechanism and what to do, in the interaction check

Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Infliximab in 16 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All infliximab products

Authorised across Europe · EMA

The same active substance is authorised in 3 EEA countries. Names it is sold under:

Iceland · Remicade, Remsima
Liechtenstein · Remicade, Remsima
Norway · Remicade, Remsima

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FAMHP / AFMPS (Belgium). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload

GET /v1/drugs/e1934df6-8f2b-4a76-b83b-5842db6c8048
GET /v1/drugs/e1934df6-8f2b-4a76-b83b-5842db6c8048?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Solution for injection in pre-filled pen",
  "source": "afmps",
  "status": "AUTHORIZED",
  "name_en": "Remsima 120 mg",
  "name_fr": "Remsima 120 mg",
  "name_nl": "Remsima 120 mg",
  "amp_code": "SAM562897-00",
  "strengths": [
    "120.0000",
    "120.0000",
    "120.0000",
    "45.0000",
    "45.0000"
  ],
  "pack_count": 10,
  "substances": [
    "Infliximab",
    "Sodium Acetate Trihydrate",
    "Sorbitol",
    "Polysorbate 80"
  ],
  "medicine_type": "ALLOPATHIC",
  "atc_description": "Infliximab",
  "authorisation_numbers": [
    "EU/1/13/853/017",
    "EU/1/13/853/012",
    "EU/1/13/853/013",
    "EU/1/13/853/014",
    "EU/1/13/853/028"
  ]
}

API reference MCP server Plans

See everything about infliximab.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it free Open in the console